Skip to main content

Immunotherapy (Investigational)

19 molecules in this therapeutic area. Open any product for its details, or send an inquiry directly.

Connect With Us

Immunotherapy (Investigational) (19)

Obrixtamig

Immunotherapy (Investigational)

Therapeutic Category

Immunotherapy (Investigational)

Oncology Type

Solid Tumour

Drug Class / Mechanism

Bispecific T-Cell Engager, DLL3 x CD3

Rilotumumab

Immunotherapy (Investigational)

Therapeutic Category

Immunotherapy (Investigational)

Oncology Type

Solid Tumour

Drug Class / Mechanism

Costimulatory / Bispecific Agent

Tarlatamab

Immunotherapy (Investigational)

Therapeutic Category

Immunotherapy (Investigational)

Oncology Type

Solid Tumour

Drug Class / Mechanism

Costimulatory / Bispecific Agent

TTI-621 (Cibisatamab-related)

Immunotherapy (Investigational)

Therapeutic Category

Immunotherapy (Investigational)

Oncology Type

Hematologic

Drug Class / Mechanism

CD47 (Macrophage Checkpoint) Inhibitor

Urelumab

Immunotherapy (Investigational)

Therapeutic Category

Immunotherapy (Investigational)

Oncology Type

Solid Tumour

Drug Class / Mechanism

Costimulatory / Bispecific Agent

Utomilumab

Immunotherapy (Investigational)

Therapeutic Category

Immunotherapy (Investigational)

Oncology Type

Solid Tumour

Drug Class / Mechanism

Costimulatory / Bispecific Agent

Vopratelimab

Immunotherapy (Investigational)

Therapeutic Category

Immunotherapy (Investigational)

Oncology Type

Solid Tumour

Drug Class / Mechanism

Costimulatory / Bispecific Agent